Biotech

All Articles

Actinogen's cortisol blocker stops working period 2 clinical depression study

.Actinogen Medical's cortisol blocker has missed the key endpoint of a period 2 study in clinical de...

Bivictrix decides going private only means to take ADC in to center

.Antibody-drug conjugates (ADCs) have actually been at the facility of a lot of a billion-dollar bio...

TPG bests up funds to $580M for financial investments across lifestyle scientific researches

.Asset supervisor TPG, which has supported biotechs such as Sionna Therapeutics as well as Santa Cla...

Merck quits period 3 TIGIT test in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT course has actually endured yet another problem. Months after shuttering a p...

After a challenging year, Exscientia folds up in to Recursion

.After a year defined by pipeline hairstyles, the variation of its own chief executive officer and a...

Cullinan, after $25M package, return bispecific to Port

.Cullinan Therapy was actually impressed good enough with Port BioMed's bispecific invulnerable acti...

A nearer take a look at Tough Biotech's Brutal 15

.Within this full week's episode of "The Leading Line," we are actually diving right into Ferocious ...

Lilly encounters period 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's gathering commemorating the approval of Alzhei...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of substantial management hirings, firings as...

Lykos will definitely ask FDA to reevaluate its decision observing rejection of MDMA treatment for post-traumatic stress disorder

.Following an unsatisfactory revealing for Lykos Rehabs' MDMA prospect for post-traumatic stress dis...